Analyst Jeet Mukherjee of BTIG reiterated a Buy rating on Perspective Therapeutics, retaining the price target of $14.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jeet Mukherjee’s rating is based on a combination of factors that highlight the potential of Perspective Therapeutics despite recent setbacks. The company’s VMT-a-NET program showed a lower objective response rate (ORR) compared to previous data and competitor programs, which initially led to a decline in stock value. However, Mukherjee notes the potential for improved response rates with extended follow-up periods, as the delayed tumor kinetics in neuroendocrine tumors (NETs) may result in better outcomes over time.
Moreover, the company’s broader enrollment criteria, particularly concerning SSTR2 expression, could lead to more favorable results when data is analyzed under stricter criteria similar to those of competitor trials. The safety profile of the VMT program is also seen as a significant advantage, especially in a patient population benefiting from prolonged progression-free survival (PFS). With upcoming data releases and enrollment updates expected, Mukherjee maintains a positive outlook on CATX, reiterating a Buy rating and a price target of $14.
In another report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $18.00 price target.